CIBC Asset Management Inc Purchases 381 Shares of Hologic, Inc. (NASDAQ:HOLX)

CIBC Asset Management Inc lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,734 shares of the medical equipment provider’s stock after purchasing an additional 381 shares during the quarter. CIBC Asset Management Inc’s holdings in Hologic were worth $1,296,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its holdings in Hologic by 141.4% in the second quarter. SG Americas Securities LLC now owns 78,026 shares of the medical equipment provider’s stock worth $4,447,000 after acquiring an additional 45,699 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Hologic by 102.9% in the second quarter. Exchange Traded Concepts LLC now owns 5,508 shares of the medical equipment provider’s stock worth $314,000 after acquiring an additional 2,794 shares in the last quarter. State Street Corp boosted its holdings in Hologic by 1.2% in the first quarter. State Street Corp now owns 11,584,851 shares of the medical equipment provider’s stock worth $406,628,000 after acquiring an additional 137,837 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Hologic by 1.7% in the first quarter. Alliancebernstein L.P. now owns 418,358 shares of the medical equipment provider’s stock worth $14,684,000 after acquiring an additional 7,087 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Hologic by 1.7% in the first quarter. The Manufacturers Life Insurance Company now owns 1,401,237 shares of the medical equipment provider’s stock worth $49,183,000 after acquiring an additional 22,798 shares in the last quarter. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Hologic stock opened at $69.78 on Friday. The stock has a market cap of $18.07 billion, a PE ratio of 27.05, a price-to-earnings-growth ratio of 3.69 and a beta of 1.47. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.04 and a current ratio of 1.47. Hologic, Inc. has a one year low of $26.49 and a one year high of $70.35. The stock has a fifty day moving average of $57.42 and a 200 day moving average of $50.06.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.37. The company had revenue of $822.90 million during the quarter, compared to analysts’ expectations of $622.96 million. Hologic had a return on equity of 31.40% and a net margin of 20.03%. Hologic’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 earnings per share. As a group, sell-side analysts predict that Hologic, Inc. will post 2.42 EPS for the current fiscal year.

Several equities research analysts have commented on the company. William Blair reissued an “outperform” rating on shares of Hologic in a report on Monday, July 27th. BidaskClub raised Hologic from a “hold” rating to a “buy” rating in a report on Saturday. JPMorgan Chase & Co. upped their price target on Hologic from $45.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating and set a $52.00 price target on the stock. in a report on Tuesday, April 28th. Finally, Citigroup upped their price target on Hologic from $63.00 to $85.00 and gave the company a “buy” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $65.38.

In other Hologic news, Director Sally Crawford sold 31,950 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $51.99, for a total value of $1,661,080.50. Following the completion of the sale, the director now owns 126,847 shares in the company, valued at $6,594,775.53. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Peter J. Valenti III sold 10,493 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $51.82, for a total value of $543,747.26. The disclosure for this sale can be found here. In the last 90 days, insiders sold 243,932 shares of company stock valued at $12,507,250. Company insiders own 1.00% of the company’s stock.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: How can investors benefit from after-hours trading?

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.